Chemotherapeutic drug scavenger-based combination therapy toward treating triple-negative breast cancer
{{output}}
Triple-negative breast cancer (TNBC) is resistant to most antitumor treatments, leaving chemotherapy as the primary option. Although doxorubicin (Dox) in combination with other therapies is promising for TNBC management, the combined effect is still compromise... ...
